Fungal Infections

Onychomycosis is a stubborn fungal infection of the nails that can be difficult to manage. Clinical trial data of Tavaborole is considered, as it allows for effective nail penetration compared to ciclopirox and amorolfine lacquers.

Onychomycosis is a common nail disorder for which successful treatment can be clinically challenging. Diagnosis, treatment, and management using various modalities are discussed.

Nail fungus, left untreated, the infection can spread to other nails and potentially cause further complications. This article reviews efinaconazole 10% as a topical monotherapy. Clinical trial data, mechanism of action, and future treatments are discussed.

Device-based therapies are promising alternatives for the treatment of onychomycosis because they can mitigate some of the negative factors associated with treatment failure. This article reviews the case for laser and light based therapies, for the treatment of nail fungus.

Vulvovaginal diseases commonly are inadequately diagnosed and treated. This article discusses the important role dermatologists play in identifying irregular presentations, recognizing skin problems, and addressing itch, pain, and inflammation.

Onychomycosis is one of the most common nail disorders. Despite recent therapeutic advances with the introduction of effective systemic agents and transungual drug delivery systems, the incidence of onychomycosis is increasing.

There has been much discussion about the optimal treatment for onychomycosis. We propose a simple algorithmic approach to aid in the selection of therapy for dermatophyte toenail onychomycosis and present a balance between efficacy and risk of therapy.

A top down overview of the available treatments for fungal infections, as well as the limitations of these therapies.

Fungal infections can affect the hair and nails as well as the skin. This article reviews the various conditions that can arise from fungal infections, and their treatments.

Clotrimazole is available in a variety of dosage forms, including oral lozenges and vaginal formulations.The mechanism of action, as well as side effects, and their indications are discussed.

Ciclopirox olamine is a hydroxypyridone antifungal that is used to treat fungal infections. Indication, brand names, therapeutic regimen, and safety information are discussed.

Itraconazole is an antifungal azole, and its use, indication, potential contraindications, and adverse events and drug interactions are discussed in this article.

Fluconazole is an antifungal azole, and its use, indication, potential contraindications, and adverse events and drug interactions are discussed in this article.

Ketoconazole, its use, indication, potential contraindications, and adverse events and drug interactions are discussed in this article.

Terbinafide hydrochloride, its use, indication, potential contraindications, and adverse events and drug interactions are discussed in this article.

This article will deal with the diagnosis and treatment of common eruptions on the feet.

Diagnosis of onychomycosis can only be established with a positive culture or observation of fungus in the nail clippings. Consideration should be given to cost and possible complications before starting treatment. Recurrent disease is a problem even after a complete cure.

Onychomycosis is prevalent, and risk factors, such as old age and diabetes, are increasing. This condition has been treated using oral antifungal agents with varying degrees of success. Recently, ciclopirox nail lacquer 8% solution became the first topical agent approved in Canada for onychomycosis.

Ciclopirox (Loprox®) is a broad-spectrum antifungal medication that also has antibacterial and anti-inflammatory properties. Ciclopirox is indicated in the US for the treatment of tinea pedis, tinea corporis, pityriasis versicolor, seborrheic dermatitis, and cutaneous candidiasis.

Onychomycosis is a common disease, and there are a number of factors that may affect the duration and dosage of treatment including the type of onychomycosis, the area and thickness of nail involvement, the age of the patient, and the location of the digit that is affected.

Ciclopirox nail lacquer 8% (Penlac, Aventis Pharma) was approved by the US FDA in December 1999, as a component of a comprehensive management program, for use in immunocompetent patients who have mild to moderate onychomycosis of the fingers and toes without lunula involvement due to Trichophyton rubrum.

Onychomycosis has a significant impact on the patient. With three new, orally effective, antifungal agents, we have for the first time effective treatment that can provide benefit for a high percentage of patients. This review examines some of the areas of uncertainty and controversy.